<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003961</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067160, J9852</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J9852</secondary_id>
    <secondary_id>JHOC-98071505</secondary_id>
    <secondary_id>NCI-G99-1544</secondary_id>
    <nct_id>NCT00003961</nct_id>
  </id_info>
  <brief_title>Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome</brief_title>
  <official_title>Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) After T-Lymphocyte Depleted Allogeneic BMT for Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of
      immune cells found in bone marrow or peripheral blood.

      PURPOSE: Phase II trial to study the effectiveness of sargramostim after bone marrow
      transplantation in treating patients who have myelodysplastic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the effect of sargramostim (GM-CSF) on the progression-free 1-year survival of
           patients with myelodysplastic syndrome who have undergone T-cell-depleted CD34+
           augmented allogeneic bone marrow transplantation.

      OUTLINE: All patients receive elutriated, CD34+ stem cell augmented donor bone marrow
      according to another protocol on day 0.

      Patients receive sargramostim (GM-CSF) subcutaneously on days 5-60.

      Patients are followed on days 120, 180, 360 and periodically thereafter.

      PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study within 3-4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Cytologically proven myelodysplastic syndrome (MDS) of one of the following types:

               -  Refractory anemia with excess blasts (RAEB)

               -  RAEB in transformation

               -  Chronic myelomonocytic leukemia

               -  MDS with multiple chromosomal abnormalities

               -  MDS with life threatening cytopenias in at least 2 cell lines

                    -  Platelet count &lt; 30,000/mm^3 OR

                    -  Absolute neutrophil count no greater than 1,000/mm^3 OR

                    -  Anemia requiring transfusion support

               -  Leukemia out of MDS (meet any of above requirements, but greater than 30% blasts
                  in marrow)

          -  No acute leukemia

          -  Medically eligible for bone marrow transplant according to standard operating
             procedure of the Sidney Kimmel Cancer Center at Johns Hopkins Blood and Bone Marrow
             Transplant

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 65

        Performance status:

          -  ECOG 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  See Disease Characteristics

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  No prior acute allergic reactions to sargramostim (GM-CSF)

          -  Not pregnant

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>B. Douglas Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 16, 2014</last_update_submitted>
  <last_update_submitted_qc>April 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>refractory cytopenia with multilineage dysplasia</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

